CX 04328

CAS No. 957890-42-5

CX 04328( LEDGIN-6 )

Catalog No. M16841 CAS No. 957890-42-5

CX 04328 (LEDGIN-6) is an allosteric HIV-1 integrase inhibitor that inhibits the LEDGF/p75-integrase interaction with IC50 of 1.37 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 262 In Stock
50MG 1188 In Stock
100MG 1791 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CX 04328
  • Note
    Research use only, not for human use.
  • Brief Description
    CX 04328 (LEDGIN-6) is an allosteric HIV-1 integrase inhibitor that inhibits the LEDGF/p75-integrase interaction with IC50 of 1.37 uM.
  • Description
    CX 04328 (LEDGIN-6) is an allosteric HIV-1 integrase inhibitor that inhibits the LEDGF/p75-integrase interaction with IC50 of 1.37 uM, antiviral activity EC50 of 2.35 uM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    LEDGIN-6
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    957890-42-5
  • Formula Weight
    353.846
  • Molecular Formula
    C21H20ClNO2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL 282.61 mM; H2O : < 0.1 mg/mL
  • SMILES
    CCCC(C1=C(C2=CC=CC=C2)C3=CC(Cl)=CC=C3N=C1C)C(O)=O
  • Chemical Name
    2-(6-chloro-2-methyl-4-phenylquinolin-3-yl)pentanoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Christ F, et al. Nat Chem Biol. 2010 Jun;6(6):442-8.
molnova catalog
related products
  • DMJ-I-228

    A small molecule CD4-mimetic that binds gp120 and blocks CD4 binding, inhibits HIV-1 entry with IC50 of 86.9 uM.

  • GS-9822

    GS-9822 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 3 nM.

  • ZBMA-1

    ZBMA-1 is a potent HIV-1 replication inhibitor (IC50=1.01 uM) that efficiently protects APOBEC3G protein by targeting Vif-APOBEC3G complex.